Heart failure & cardiomyopathiesRandomised controlled trial
The Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A European Health-Economic Analysis of the DELIVER Trial
- Cost-effectiveness analysis of the DELIVER randomised trial
- lifetime Markov state-transition cohort model
- patient-level data
- probabilistic sensitivity analyses
Authors' conclusion
Dapagliflozin, added to usual care, is very likely cost-effective for HF with mildly reduced or preserved ejection fraction in several European countries.
Study context
- Population
- Patients with heart failure (HF) with mildly reduced or preserved EF; UK, German and Spanish payers
- Comparison
- Dapagliflozin added to usual care vs usual care
- Primary endpoint
- Incremental cost-effectiveness ratio (cost per QALY)
- Follow-up
- Lifetime
Primary result
As reported in the abstract
ICER per QALY
ICER, UK
£7761/QALY
ICER, Germany
€9540/QALY
ICER, Spain
€5343/QALY
Further findings
Incremental quality-adjusted life years (QALYs), life-years and time in best Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS) quartile (UK)
- QALYs gained
- 0.231
- Life-years gained
- 0.354
- Additional time in best KCCQ-TSS quartile
- 4.2 months
- Comparable outcomes projected for Germany and Spain
Simulations cost-effective at regional willingness-to-pay thresholds (probabilistic sensitivity analyses)
- UK
- 91%
- Germany
- 89%
- Spain
- 92%
Original publication
The Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A European Health-Economic Analysis of the DELIVER Trial. Eur J Heart Fail. Published 11 July 2023. doi:10.1002/ejhf.2940
Summarised from the published abstract; every number is checked against it